MAPT and Alzheimer disease: Only one drug, LMTX (TRx0237) — a reduced form of methylene blue, and a tau protein aggregation inhibitor -- is currently being tested in a Phase 3 trial in early AD at 8 — 16 mg/day doses versus placebo (NCT03446001).